Buformin
Based on 3 publication(s) in Google Scholar
Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al).
For research use only. We do not sell to patients.
- CAS No.: 692-13-7
- Formula: C6H15N5
- Molecular Weight:157.22
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Buformin
MoreAll AMPK Isoforms
More
Biological Activity
Buformin (0-10 mM; 5 days) inhibits SKBR3 and BT474 cells growth as a concentration-dependent manner, exhibits IC50 values of 246.7 μM and 98.6 μM for erbB-2-overexpressing SKBR3 and BT474 cells, respectively[1].Buformin (0-3 mM; 48 hours) increases the percentage of cells in G0/G1 phase and reduced the percentage of cells in S phase, especially in the SKBR3 cells[1].Buformin (0-3 mM; 24 hours) suppresses RTK activation, including erbB-2 and IGF1R signaling downstream, and Akt activation/phosphorylation is inhibited in both SKBR3 and BT474 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:ErbB-2-overexpressing SKBR3 and BT474 cells
-
Concentration:0 μM, 1 μM, 3 μM, 10 μM, 30 μM, 100 μM, 300 μM, 1, 3, or 10 mM
-
Incubation Time:5 days
-
Result:Reduced cell viability in erbB-2-overexpressing breast cells.
-
Cell Line:ErbB-2-overexpressing SKBR3 and BT474 cells
-
Concentration:0.5 mM; 1 mM; 3 mM
-
Incubation Time:48 hours
-
Result:Increased cells arresting in G0/G1 phase.
-
Cell Line:ErbB-2-overexpressing SKBR3 and BT474 cells
-
Concentration:0 mM, 0.1 mM, 0.3 mM, 1 mM, or 3 mM
-
Incubation Time:24 hours
-
Result:Decreased p-AMPK, p-p706S, p-ERK1/2 expression in a concentration-dependent manner.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female MMTV-erbB-2 transgenic mice[1]
-
Dosage:7.6 mmol/kg
-
Administration:Oral administation; 7 days
-
Result:Inhibited mammary syngeneic tumor growth in MMTV-erbB-2 transgenic mice.
Chemical Information
-
CAS No. 692-13-7
-
Molecular Weight 157.22
-
Formula C6H15N5
-
SMILES
NC(NC(NCCCC)=N)=N
-
Synonyms
1-Butylbiguanide
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Clin Sci
Buformin alleviates sepsis-induced acute lung injury via inhibiting NLRP3-mediated pyroptosis through an AMPK-dependent pathway. [Abstract]2022 Feb 25;136(4):273-289. PMID: 35132999 -
Mol Metab
Developmental metformin exposure does not rescue physiological impairments derived from early exposure to altered maternal metabolic state in offspring mice. [Abstract]2024 Jan:79:101860. PMID: 38142972 -
Purity & Documentation
References
[1]. Amanda B Parris, et al. Buformin Inhibits the Stemness of erbB-2-overexpressing Breast Cancer Cells and Premalignant Mammary Tissues of MMTV-erbB-2 Transgenic Mice. J Exp Clin Cancer Res [Content Brief]
[2]. Jing Li, et al. Buformin Suppresses Proliferation and Invasion via AMPK/S6 Pathway in Cervical Cancer and Synergizes With Paclitaxel. Cancer Biol Ther. 2018 Jun 3;19(6):507-517. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz